Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
cbdMD ( (YCBD) ) has issued an update.
On September 30, 2025, cbdMD, Inc. finalized Securities Purchase Agreements with four institutional investors, resulting in the issuance of 1,700,000 shares of Series B Convertible Preferred Stock for $1,700,000, with net proceeds of $1,500,000 allocated for working capital. The Series B Preferred Stock, convertible into common stock and accruing dividends at 10% per annum, positions cbdMD to strengthen its financial base, although it includes restrictions such as a 4.99% beneficial ownership limit and no voting rights for holders, potentially impacting investor influence.
The most recent analyst rating on (YCBD) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on cbdMD stock, see the YCBD Stock Forecast page.
Spark’s Take on YCBD Stock
According to Spark, TipRanks’ AI Analyst, YCBD is a Underperform.
The overall stock score is heavily impacted by significant financial challenges, including negative income and cash flows, high leverage, and declining revenues. Technical analysis provides some mixed signals, but the long-term trend remains bearish. Valuation metrics further highlight the company’s financial struggles, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on YCBD stock, click here.
More about cbdMD
cbdMD, Inc. operates in the wellness industry, focusing on the production and sale of cannabidiol (CBD) products. The company targets consumers seeking natural health and wellness solutions.
Average Trading Volume: 3,470,128
Technical Sentiment Signal: Sell
Current Market Cap: $10.34M
For detailed information about YCBD stock, go to TipRanks’ Stock Analysis page.